ABC of health informatics Improving services with informatics tools
Frank Sullivan, Jeremy C Wyatt This article describes how many sources of data can be linked, interpreted, and analysed before being presented to decision makers to improve care. It also discusses the legal issues surrounding data protection and freedom of information.
A huge volume of data flows across the desk of a director of public health (see box opposite). One of the director's problems is to know which signals to act upon and what "noise" to ignore. If the numbers being considered are small, as they probably will be in the case described here, a critical incident analysis may be all that is needed. An individual prescriber, or group, may have an erroneous belief or inadequate training. Critical incidents or other signals often indicate that more data (such as data on prescribing steroids for paediatric asthma in primary care and outpatients) are needed.
Sources of data
Health services are awash with data. Earlier articles in the series described the large and increasing numbers of sources of data available to consumers, patients, clinicians, and administrators. Clinicians, teams, divisions, and other groups collect the data they need to carry out their work, and they may do so using coding and terms that others can understand and share. The intensive care unit in this example integrated the data the team needs to manage patients during their stay with patients' pre-admission prescribing data. This local epidemiology may have been done as part of clinical governance activities, or as an ad hoc exercise when a patient's problem was investigated.
One difficulty with secondary uses of clinical data is that, having obtained the data indicating a problem exists, the issue must be dealt with effectively. It may be that the individual or group who identify the problem have the knowledge, skills, and resources to resolve it. In other cases, such as these potentially avoidable asthma admissions, those responsible are not those who have uncovered the issue, and those potentially responsible may be unaware of the problem.
Presentation of data
Ideally, the choice of measures, analysis, and presentation of data should be determined by the purpose of measurement and the use to which data are to be put. This poses another difficulty with the secondary use of clinical data. Studies have shown that interpretation of data is influenced by the method used to summarise the results. Health policy makers, like doctors, tend to prefer measurements that report relative risks (or benefits) to measurements providing estimates of absolute risks (or benefits). Once the decision has been taken to act on data, how best to present the information should be considered.
Feedback of performance data
Different approaches (using internal or external influences on decision makers) can be taken when using data to improve care. The interventions chosen should be tailored to the underlying problem. At least two, and preferably three, of the more effective approaches (see boxes on next page) should be taken.
UK clinical governance definition*
A framework through which NHS organisations are accountable for continually improving the quality of their services and safeguarding high standards of care by creating an environment in which excellence in clinical care will flourish *From Scally G, Donaldson LJ. Clinical governance and the drive for quality improvement in the new NHS in England. BMJ 1998; 317:61-5 Categories of improvement for health services* Today, it is less necessary to rely on individual clinicians or teams to produce routine reports because computerised data entry enables the routine extraction of data for many purposes. Data from multiple sources may be linked to records, and so provide additional intelligence beyond the purposes for which they were originally collected.
Record linkage
Deterministic or probabilistic methods can be used with similar success rates to link records. In the former case, a unique patient identifier, such as a 10 digit community health index number, is applied to all personal health data-for example, laboratory test requests and prescriptions. In the latter case, algorithms determine the likelihood that two items of data belong to the same person. The Soundex system converts a name to a code (for example, Michael becomes M240). The first letter is the first letter of the word, and the numbers represent phonetic parts of latter syllables. The algorithm determines that John Smyth and John Smythe is the same child with asthma if sufficient other characteristics (date of birth, street name) on the admission data and community prescriptions match. After linkage, each individual item of data may then be linked and anonymised for disease surveillance purposes. protection. It aims to ensure that the processing (obtaining, recording, holding, doing calculations on) of information using data is done in accordance with the rights of individuals. The European directive also extends the legislation to manual, as well as computerised, records containing personal information. Under the provisions of the act, data controllers (for example, general practitioners) are responsible for ensuring that access to patient data should be under strictly controlled conditions and, if necessary, with patients' consent.
Data protection
Eight principles of good practice are in the act. Patients should be aware, at least in broad terms, of the purposes for which their personal data are used. However, it is the view of the data protection registrar that consent should normally be obtained when processing data about a patient's health. Many Caldicott guardians believe that the activities of the NHS are often in the public interest, and in most cases the consent of the patient can be inferred. Other bodies, such as the General Medical Council and the BMA, advise that explicit consent is still preferable in some cases, and examples include: x Release of details of patients to diabetic and cancer registers x Release of summaries of patient date to out of hours services.
The 2000 Freedom of Information Act came into force in January 2005. It is intended to "promote a culture of openness and accountability amongst public sector bodies by providing people with rights of access to the information held by them." It will probably conflict with data protection legislation because information about individuals is contextualised within families, communities, practices, and hospital units. It will be difficult to ensure that an individual's data are protected while giving freedom of information to others within that context.
Feedback of information
In many medical cultures it is difficult to provide feedback that will be taken in a constructive manner. Certain principles make it more likely that the feedback will be considered constructive by recipients, and changes that could improve care will probably be implemented.
Research governance
Confidentiality and security of data is probably a greater concern for researchers than clinicians, although clinical researchers need to live with concept of governance in both worlds. Data collected for patient care may only be used to produce research evidence with adequate safeguards for the patients. Legislation varies between countries, but the highest standards apply to use of personally identifiable data, where explicit signed, informed consent is often required. Some jurisdictions relax this standard if it is impossible, or extremely difficult, to obtain the consent. In other countries acceptable anonymisation and adherence to rules of good epidemiological practice allow the use of clinical data for research purposes.
Summary
A public health consultant faced with complex, difficult choices, such as the data on asthma prescribing, will prefer to discuss the reasons for apparent prescribing failures rather than taking pre-emptive action, which may do harm to the service overall. The factors that caused the presenting problem are often rooted in the culture of the health system, and so the solution often means changing the system. The consequences of failing to act when there is a problem need to be counterbalanced against the damage caused by incorrect interpretation of data collected for one purpose but used for another.
Principles of good practice in the 1998 Data Protection Act
Data are: x Fairly and lawfully processed x Processed for limited purposes x Adequate, relevant, and not excessive x Accurate x Not kept longer than necessary x Processed in accordance with the rights of the subject of the data x Secure x Not transferred to countries without adequate protection Dame FIONA Caldicott's principles of data processing*
x Formal justification of purpose x Information transferred only when absolutely necessary x Only the minimum required x Need to know access controls x All to understand their responsibilities x Comply with and understand the law likely to be promoted may in part reflect this. Investigating this point would require complete data on employment history since graduation. The data will also include doctors in the training grades who may not want to become a consultant, and the results may be partly reflecting the preferences of this group, who are more likely to be female and work part time. However, this group is likely to be small.
Conclusions
The achievement of current government targets for the numbers of consultants are influenced by the promotion process and the quality control exercised by the royal colleges. As the proportion of female doctors increases, it will be difficult to meet government targets unless the promotion process is re-examined. This should focus on the weight given to individuals' skills and ability and the flexibility of contracts and working conditions. Safeguards will need to be in place to ensure that factors less likely to be related to ability or performance (such as sex, place of graduation, or part time working) will not influence promotion chances. 
Corrections and clarifications

Achieving the millennium development goals for health: Cost effectiveness analysis of strategies to combat malaria in developing countries
A mix-up during submission led to the wrong version of table 3 being included in the full version of this paper (see bmj.com) by Chantal M Morel and colleagues (BMJ 2005; 331:1299-302, 3 Dec) . The R 0 value for case management with chloroquine should be 0.35 (rather than 0.3). The adherence for artemisinin based combination treatment should be 35% (not 40%), and neither that nor the adherence for non-artemisinin based treatment needs a footnote. Values for probability of success when patients were not fully compliant should be 35% for non-artemisinin based treatment and 0% for intermittent presumptive treatment during pregnancy (rather than 35% and 10% respectively, as given). These revised values also apply to table B on bmj.com. 
ABC of health informatics: Improving services with informatics tools
Primary care in the United States: problems and possibilities
Electronic difficulties while handling the proofs led to an error and an omission in this article by Robert L Phillips (BMJ 2005;331:1400-2,10 Dec). The author's job title was wrong; he is in fact director of the Robert Graham Center. In addition, the article should have contained the following disclaimer: "The information and opinions contained in research from the Graham Center do not necessarily reflect the views or policy of the American Academy of Family Physicians."
Extra scrutiny for industry funded trials
The title of this editorial by Kenneth J Rothman and Stephen Evans (BMJ 2005;331:1350-1, 10 Dec) should have referred to "studies," not "trials." The authors discussed all reports containing original data, so "studies" would have been more accurate. The use of the word "trials" was the result of a late editorial intervention.
Treatment of bites by adders and exotic venomous snakes
In this Clinical Review by David A Warrell, the author's email address was wrong (BMJ 2005; 331:1244-7, 26 Nov) . The correct address is david.warrell@ndm.ox.ac.uk
Randomised placebo controlled multicentre trial to assess short term clarithromycin for patients with stable coronary heart disease: CLARICOR trial
The main text and the summary box in this paper by Christian M Jespersen and colleagues (BMJ 2006; 332:22-4, 7 Jan) refer to the patients in the trial being followed for up to three years. The authors have clarified that the mean follow-up was 960 (range 900-1070) days.
